SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

A Meaningful Step Forward in Stent Technology

The SYNERGY BP Stent is the first and only FDA-approved drug-eluting stent with abluminal bioabsorbable polymer coating available in the U.S. It was designed to address the challenges associated with permanent polymer stents such as inflammation, neoatherosclerosis and late stent thrombosis.

The SYNERGY BP Stent provides synchronous drug elution and polymer absorption; the polymer is absorbed shortly after the drug elution is complete at 3-months, providing rapid healing and freedom from long-term polymer exposure. Learn more

Watch Video: EVOLVE Short DAPT Trial Enrollment Complete

Boston Scientific has invested in short DAPT clinical trials designed to study various patient populations commonly treated by physicians. Prof. Ian Meredith, EVP and Global Chief Medical Officer with Boston Scientific discusses the EVOLVE Short DAPT Trial and this important milestone.
EVOLVE Short DAPT Trial: Enrollment Complete

SYNERGY BP Stent Short DAPT Data

The SYNERGY BP Stent showed superior results versus BMS in elderly patients that received a shortened DAPT* regimen in the SENIOR Trial. View the data

 
Early Healing

Early Healing

Advanced design for optimal healing

Button
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Efficiency

Efficiency

How design impacts economic value

Button
Top